智通财经APP获悉，基石药业-B(02616)早盘涨超5%，截至发稿，涨7.41%，报7.39港元，成交额5465.48万港元。
消息面上，基石药业公布，已在2025 ESMO大会上首次发表CS2009(PD1/VEGF/CTLA-4三特异性抗体)的I期临床研究初步数据，以及CS5001(ROR1抗体偶联药物 ADC)的Ib期临床研究设计。
值得注意的是，根据香港联交所最新资料，GIC于10月13日披露再度增持基石药业，持股比例达到6%。据悉，这是GIC在不到两个月内的第二次大举增持——此前8月18日，GIC曾大手笔增持基石药业8040万股股份，耗资超6.3亿港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.